Watari K, Asano S, Shirafuji N, Kodo H, Ozawa K, Takaku F, Kamachi S
Department of Hematology-Oncology, Institute of Medical Science, University of Tokyo, Japan.
Blood. 1989 Jan;73(1):117-22.
In order to better understand the patho-physiologic role of granulocyte colony-stimulating factor (G-CSF), we estimated its serum levels in healthy persons and patients with various disorders, using a newly developed enzyme immunoassay (Motojima et al). In 49 of 56 normal healthy persons (88%), the levels were beneath the sensitivity of the assay (less than 30 pg/mL), while in the remaining seven healthy persons, the levels ranged from 33 to 163 pg/mL. On the other hand, nine of 11 patients (82%) with idiopathic aplastic anemia (AA), one patient with Fanconi's anemia, six of 12 patients (50%) with myelodysplastic syndrome (MDS), five of 12 patients (42%) with acute leukemia without any blast cells in the blood (M4: one, M5: one, L1: one, and L2: two), six of 18 patients (33%) with chronic myeloid leukemia (CML), one of two patients with chronic lymphoid leukemia (CLL), two of four patients with lung cancer, one patient with cyclic neutropenia, two of seven patients with malignant lymphoma, and four patients with acute infection had G-CSF levels ranging from 46 pg/mL to greater than 2,000 pg/mL. Interestingly, a reverse correlation between blood neutrophil count and serum G-CSF level was clearly demonstrated for aplastic anemia (r = -.8169, P less than .01). Moreover, it was found that the G-CSF level rose during the neutropenic phase of cyclic neutropenia and after chemotherapy or bone marrow transplantation (BMT) in three patients with leukemia; also high G-CSF levels were positively correlated to blood neutrophil counts in some cases of infectious disorders and lung cancer. The cellular sources and the mechanisms for production and secretion of circulating G-CSF were not investigated in this study, but the data presented here strongly indicate that G-CSF plays an important role as a circulating neutrophilopoietin.
为了更好地理解粒细胞集落刺激因子（G-CSF）的病理生理作用，我们使用新开发的酶免疫测定法（本岛等人），对健康人和患有各种疾病的患者的血清G-CSF水平进行了评估。在56名正常健康人中，有49人（88%）的水平低于该测定法的灵敏度（低于30 pg/mL），而其余7名健康人的水平在33至163 pg/mL之间。另一方面，11例特发性再生障碍性贫血（AA）患者中有9例（82%）、1例范可尼贫血患者、12例骨髓增生异常综合征（MDS）患者中有6例（50%）、12例血液中无原始细胞的急性白血病患者中有5例（42%）（M4：1例、M5：1例、L1：1例、L2：2例）、18例慢性髓性白血病（CML）患者中有6例（33%）、2例慢性淋巴细胞白血病（CLL）患者中有1例、4例肺癌患者中有2例、1例周期性中性粒细胞减少症患者、7例恶性淋巴瘤患者中有2例以及4例急性感染患者的G-CSF水平在46 pg/mL至大于2000 pg/mL之间。有趣的是，再生障碍性贫血患者的血液中性粒细胞计数与血清G-CSF水平之间呈现明显的负相关（r = -0.8169，P < 0.01）。此外，还发现周期性中性粒细胞减少症的中性粒细胞减少期以及3例白血病患者化疗或骨髓移植（BMT）后G-CSF水平升高；在某些感染性疾病和肺癌病例中，高G-CSF水平也与血液中性粒细胞计数呈正相关。本研究未探讨循环G-CSF的细胞来源以及产生和分泌机制，但此处呈现的数据有力地表明，G-CSF作为一种循环中的促中性粒细胞生成素发挥着重要作用。
